Tag: Prescription Drugs

Inavolisib leads to significantly longer progression-free survival, with no increase seen in incidence of toxic events

Findings seen in patients with IgA nephropathy, compared with placebo

Inhaled corticosteroid with short-acting β agonists or long-acting β agonist formoterol linked to reduction in exacerbations, improved control

Guidelines include 52 recommendations on evaluation, pharmacotherapy, invasive interventions, and nonpharmacologic interventions

Rifaximin monotherapy reduces risk for breakthrough OHE episode and results in a lower mortality rate than lactulose monotherapy

Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among CKD patients at risk for progression

Second study shows that only 14 percent of patients correctly identified symptoms requiring epinephrine

Reduction of 75 and 77 percent seen in estimated mean monthly attack rate with 25-mg, 50-mg NTLA-2002 versus placebo

Corneal toxicity not uncommon with MIRV treatment for primary gynecologic malignancies, usually resolves

Barriers include access to treatment, insurance barriers, and financial issues